We have previously shown that W nt5 A drives invasion in melanoma. We have also shown
that W nt5 A promotes resistance to therapy designed to target the BRAF V600E mutation in …

Metastatic dissemination remains a significant barrier to successful therapy for melanoma.
Wnt5A is a potent driver of invasion in melanoma and is believed to be secreted from the …

The outgrowth of metastatic and therapy-resistant subpopulations in cancer remains a
critical barrier for the successful treatment of this disease. In melanoma, invasion and …

Metastatic melanoma is an aggressive disease, despite recent improvements in therapy.
Eradicating all melanoma cells even in drug-sensitive tumors is unsuccessful in patients …

Although the clinical landscape of melanoma is improving rapidly, metastatic melanoma
remains a deadly disease. Age remains one of the greatest risk factors for melanoma, and …

Extensive research has demonstrated a tumor-promoting role of increased WNT5A
expression in malignant melanoma. However, very little light has been shed upon how …

Cellular senescence is an initial barrier for carcinogenesis. However, the signaling
mechanisms that trigger cellular senescence are incompletely understood, particularly in …

Purpose: Wnt ligands play a major role in development and are important in cancer.
Expression microarray analysis correlates one member of this family, WNT5A, to a subclass …

The interplay between canonical and non‐canonical Wnt pathways in development and
tumorigenesis is tightly regulated. In this review we will describe the yin and the yang of …

There are currently no effective therapies for metastatic melanoma and targeted
immunotherapy results in the remission of only a very small percentage of tumors. In this …